Nway Biotech Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 02-11-2024
- Paid Up Capital ₹ 0.10 M
as on 02-11-2024
- Company Age 2 Year, 10 Months
- Last Filing with ROC 31 Mar 2023
- Open Charges ₹ 2.04 Cr
as on 02-11-2024
- Revenue %
(FY 2023)
- Net Worth -2146.80%
(FY 2023)
- Total Assets 1214.07%
(FY 2023)
About Nway Biotech
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.04 Cr.
Viresh Dasare and Tarun Sohinda serve as directors at the Company.
- CIN/LLPIN
U24299MH2022PTC378142
- Company No.
378142
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Mar 2022
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Company Details
- Location
Aurangabad, Maharashtra, India
- Telephone
- Email Address
- Website
-
- Social Media-
What products or services does Nway Biotech Private Limited offer?
Nway Biotech Private Limited offers a wide range of products and services, including Common Disease Medicines, Cough Syrup, Plastic Containers & Bottles, Packaging Bottles, Healthcare Products & Aids, Health Drinks, Juices, Soups & Soft Drinks, Beverages Mixes, Instant Drink Mix.
Who are the key members and board of directors at Nway Biotech?
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Viresh Dasare  | Additional Director | 30-Aug-2022 | Current |
| Tarun Sohinda | Director | 09-Mar-2022 | Current |
Financial Performance of Nway Biotech.
Nway Biotech Private Limited, for the financial year ended 2023, experienced no change in revenue, with a 0% increase. The company also saw a no change in profitability, with a 0% increase in profit. The company's net worth observed a substantial decline by a decrease of 2146.8%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue | |||||||
| Revenue from Operations | |||||||
| Total Assets |
| ||||||
| Profit or Loss | |||||||
| Net Worth |
| ||||||
| EBITDA |
What is the Ownership and Shareholding Structure of Nway Biotech?
Unlock access to Nway Biotech's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Others Creation Date: 28 Nov 2022 | ₹2.04 Cr | Open |
How Many Employees Work at Nway Biotech?
Nway Biotech has a workforce of 0 employees as of Apr 05, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nway Biotech, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nway Biotech's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
